Drug
Favipiravir clinical trials
Also written Avigan and T-705.
- studies test it
- 54
- open now
- 7
- in phase 3
- 21
- first study started
- 2010
Keep track of what changes. Save the favipiravir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Avigan
- 10
Development codes
Studies by the year they started
54 studies that test it; most in 2020 (35)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 35 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 26
- Phase 3
- 21
- Phase 4
- 2
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 31
Who runs them
Industry 19 · Other 35
MDVI, LLC (5) · Institut National de la Santé Et de la Recherche Médicale, France (3) · University of Oxford (3) · Appili Therapeutics Inc. (2) · King Abdullah International Medical Research Center (2) · Shin Poong Pharmaceutical Co. Ltd. (1) · Mansoura University Hospital (1) · Bernhard Nocht Institute for Tropical Medicine (1)
Often tested with
Tested in the same studies.
Hydroxychloroquine (4) · Molnupiravir (4) · Nitazoxanide (3) · Remdesivir (2) · Nirmatrelvir and ritonavir drug combination (2) · Ribavirin (2) · Artesunate (1) · Amodiaquine (1)
Studies
Open first, then newest update. How each study uses favipiravir is read from its arms, and is right about nine times in ten.
Testing it · 54
- UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHFRecruitingPhase 2Liverpool School of Tropical MedicineNCT06860334Written as Favipiravir
- AGILE (Early Phase Platform Trial for COVID-19)RecruitingPhase 1/2University of LiverpoolNCT04746183Written as Favipiravir
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaRecruitingPhase 2University of OxfordNCT05648448Written as Favipiravir
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Favipiravir
- Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy VolunteersRecruitingPhase 1Institut National de la Santé Et de la Recherche Médicale, FranceNCT06024421Written as favipiravir
- ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyRecruitingPhase 2/3Irrua Specialist Teaching HospitalNCT06212336Written as Favipiravir
- Assessing Antiviral Treatments in Early Symptomatic RSVRecruitingPhase 2University of OxfordNCT06488300Written as Favipiravir
- Efficacy of Favipiravir Against Ebola (JIKI)CompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02329054Written as Favipiravir
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19CompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT04532931Written as Favipiravir plus Nitazoxanide
- Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the SemenTerminatedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02739477Written as Favipiravir
- The Prevent Severe COVID-19 (PRESECO) StudyCompletedPhase 3Appili Therapeutics Inc.NCT04600895Written as Favipiravir
- Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 PatientsCompletedPhase 4Mansoura University HospitalNCT05502081Written as Favipiravir
- Control of COVID-19 Outbreaks in Long Term CareTerminatedPhase 2Appili Therapeutics Inc.NCT04448119Written as Favipiravir
- Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa FeverCompletedPhase 2Bernhard Nocht Institute for Tropical MedicineNCT04907682Written as Favipiravir
- Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19CompletedPhase 3R-PharmNCT04501783Written as Favipiravir
- FLARE: Favipiravir +/- Lopinavir: A RCT of Early AntiviralsCompletedPhase 2University College, LondonNCT04499677Written as Favipiravir
- Clinical Trial of Favipiravir Treatment of Patients With COVID-19CompletedPhase 3University of PecsNCT04600999Written as Favipiravir
- Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19CompletedPhase 2Stanford UniversityNCT04346628Written as Favipiravir
- Investigation the Effect of Montelukast in COVID-19Status unknownPhase 2Bahçeşehir UniversityNCT04718285Written as Montelukast plus Favicovir (Favipiravir)
- Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19CompletedPhase 2Fujifilm Pharmaceuticals U.S.A., Inc.NCT04358549Written as Favipiravir
See all 54 studies that test favipiravir →
Given in every arm · 7 — favipiravir is usual care beside what is tested
- UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHFRecruitingPhase 1/2Liverpool School of Tropical MedicineNCT05940545Written as Favipiravir
- Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19CompletedPhase 2Coordinación de Investigación en Salud, MexicoNCT04918927Written as Favipiravir
- Efficacy and Safety of Favipiravir in Covid-19 Patients in IndonesiaCompletedPhase 3Ina-RespondNCT04613271Written as Favipiravir
- Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 PatientsCompletedPhase 3RAAS Nutritionals, LLCNCT05417997Written as Favipiravir
- Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19CompletedPhase 3Promomed, LLCNCT05185284Written as Favipiravir
- Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma TherapyStatus unknownPhase 1/2Hayandra Peduli FoundationNCT04715360Written as Avigan
- Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in NepalStatus unknownPhase 3Nepal Health Research CouncilNCT04694612Written as Favipiravir
As the comparator · 4 — what is tested is compared with favipiravir
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedPhase 3PharmaMarNCT04784559Written as Favipiravir
- Efficacy and Safety of JT001 (VV116) Compared With FavipiravirTerminatedPhase 3Shanghai Vinnerna Biosciences Co., Ltd.NCT05279235Written as Favipiravir
- Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19Status unknownPhase 2/3The Scientific and Technological Research Council of TurkeyNCT04828564Written as Favipiravir
- Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019Status unknownNot applicablePeking University First HospitalNCT04310228Written as Favipiravir
Codes
What other systems call favipiravir · ClinicalTrials.gg INT004464
- MeSH (NLM) C462182favipiravirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) EW5GL2X7E0FAVIPIRAVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q16934561favipiravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81605FavipiravirOne source FDA
- DrugBank DB12466One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C462182 | favipiravir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | EW5GL2X7E0 | FAVIPIRAVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q16934561 | favipiravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81605 | Favipiravir | One source FDA |
| DrugBank | DB12466 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.